Product Description: Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody against PD-1[1].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Drouin E E, et al. AGEN1884, an IgG1 anti-CTLA-4 antibody, combines effectively with PD-1 blockade in primary human T cell assays and in a non-human primate pharmacodynamic (PD) model. Cancer Research, 2017, 77(13_Supplement): 3654-3654.
CAS Number: 2148321-77-9
Molecular Weight: N/A
Research Area: Inflammation/Immunology
Solubility: H2O
Target: PD-1/PD-L1